Figure 1
H56/CAF01-mediated protection is accompanied by accelerated recruitment of Mtb-specific T cells to the lung parenchyma. sCB6F1 mice were vaccinated and rested 6 weeks prior to aerosol Mtb challenge. (a) Total Lung CFU from adjuvant-only control (Ctrl,○) and H56/CAF01-vaccinated (H56,●) CB6F1 mice. Symbol, mean±s.d. of 5–6 mice. (b) Mice were stained i.v. with anti-CD45-FITC to distinguish parenchymal (IV–) from vasculature (IV+) cells, followed by ex vivo stimulation of lung cells with H56 protein and ICS staining for IFNγ/TNFα/IL- 2/IL-17 production to enumerate H56-specific CD4 T cells. H56-specific IFNγ production by IV+ and IV- CD4 lung cells from a control (left) and a H56/CAF01-vaccaninated (right) mouse 3 weeks after aerosol Mtb infection. (c) Total number of IV- H56-specific CD4 lung cells from adjuvant only control (○) and H56/CAF01-vaccinated (●) CB6F1 mice before and after aerosol Mtb infection, based on ICS staining for cells producing any cytokine (IFNγ,TNFα,IL-2, or IL-17). Data are pooled from three independent experiments each with 3–6 mice per time point. Symbol, mean±s.e.m. Dotted line represents assay background, i.e., mean preinfection H56-specific response in adjuvant-only control mice. *P<0.05,**P<0.01, ***P<0.001.
